This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
New research from the University of Colorado Anschutz suggests that psilocybin may help improve anhedonia, the loss of interest or ability to experience pleasure, in people with treatment-resistant depression. In a clinical trial, researchers found significant improvement in this difficult-to-treat symptom eight weeks after treatment, offering new insight into psilocybin's potential role in depression care.
Anhedonia is one of the most difficult symptoms of depression to treat. It can affect a person's ability to enjoy everyday activities, connect with others and experience a sense of meaning, even when other symptoms of depression improve.
The study, published in the Journal of Affective Disorders, is the first randomized, placebo-controlled clinical trial to specifically investigate psilocybin's effects on anhedonia in people with treatment-resistant major depressive disorder, a form of depression that has not responded adequately to previous treatments.
Researchers found that participants who received 25 milligrams of psilocybin experienced significantly greater improvement in anhedonia eight weeks after treatment compared with participants who received a 1-milligram dose.
However, the study did not find a statistically significant difference between the groups on its primary measure of anhedonia at one week. The difference observed at eight weeks was a secondary finding, suggesting that psilocybin's potential effects on this symptom warrant further investigation.
, associate professor of psychiatry at the University of Colorado Anschutz.
Source link







